In ramucirumab-treated GC patients, patients with CDH1 mutations (n = 159) exhibited significantly shorter OS (median: 4.90 vs 8.13 months, HR = 1.54, 95% CI: 1.03–2.27, p = 0.034, Fig. 2b), compared to patients with CDH1- WT tumors (n = 35). Here, CDH1 is linked to gastric cancer.